Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to novel pharmaceutical compositions based on anticholinergics and pegsunercept, processes for preparing them and their use in the treatment of respiratory diseases.
• the present invention relates to novel pharmaceutical compositions based on anticholinergics and pegsunercept, processes for preparing them and their use in the treatment of respiratory diseases.
• Pegsunercept is a PEGylated soluble tumor necrosis factor receptor with known anti- inflammatory properties.
• an unexpectedly beneficial therapeutic effect can be observed in the treatment of inflammatory and/or obstructive diseases of the respiratory tract if one or more, preferably one, anticholinergic is used with pegsunercept, a TNF binding protein.
• the pharmaceutical combinations according to the invention can be used in smaller doses than would be the case with the individual compounds used in monotherapy in the usual way.
• the effects mentioned above may be observed both when the two active substances are administered simultaneously in a single active substance formulation and when they are administered successively in separate formulations. According to the invention, it is preferable to administer the two active substance ingredients simultaneously in a single formulation.
• anticholinergics 1 denotes salts which are preferably selected from scopine-, tropanol-, and tropenolesters.
• anticholinergic agents 1 are in a preferred embodiment selected from the compounds of formula la wherein
• R 7 denotes hydrogen, methyl, ethyl, methyloxy, ethyloxy, -CH 2 -F, -CH 2 -CH 2 -F, -O-CH 2 -F, -O-CH 2 -CH 2 -F, -CH 2 -OH, -CH 2 -CH 2 -OH, CF 3 , -CH 2 -OMe, -CH 2 -CH OMe, -CH 2 -CH OMe, -CH 2 -OEt, -CH 2 -CH 2 -OEt, -O-COMe, -O-COEt, -O-COCF 3 , -O-COCF 3 , fluorine, chlorine or bromine.
• Preferred compounds of formula la within the combinations according to the invention are those, wherein X " denotes bromide;
• R 1 and R 2 which may be identical or different denote a group selected from methyl and ethyl, preferably methyl;
• R 3 , R 4 , R 5 and R 6 which may be identical or different, denote hydrogen, methyl, methyloxy, chlorine or fluorine;
• R 7 denotes hydrogen, methyl or fluorine.
• A denotes a double-bonded group selected from among ⁇ _ / C — C anrl H H H o H
• the compounds of formula la may optionally be present in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
• compositions that contain the compound of formula 2 in combination with one of the following compounds la: - tropenol 2,2-diphenylpropionic acid ester methobromide, scopine 2,2-diphenylpropionic acid ester methobromide, scopine 2-fluoro-2,2-diphenylacetic acid ester methobromide and tropenol 2-fluoro-2,2-diphenylacetic acid ester methobromide.
• anticholinergic agents 1 are in a yet another preferred embodiment selected from the compounds of formula
• A, X ", R and R may have the meanings as mentioned hereinbefore and wherein R 7 , R 8 , R 9 , R 10 , R 11 and R 12 , which may be identical or different, denote hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF 3 or NO 2 , with the proviso that at least one of the groups R 7 , R 8 , R 9 , R 10 , R 11 and R 12 is not hydrogen.
• A denotes a double-bonded group selected from among X " denotes bromide;
• R 1 and R 2 which may be identical or different denote methyl or ethyl, preferably methyl;
• R 7 , R 8 , R 9 , R 10 , R 11 and R 12 which may be identical or different, denote hydrogen, fluorine, chlorine or bromine, preferably fluorine with the proviso that at least one of the groups R 7 , R 8 , R 9 , R 10 , R 1 and R 12 not hydrogen.
• compositions that contain the compound of formula 2 in combination with one of the following compounds lb: tropenol 3,3',4,4'-tetrafluorobenzilic acid ester methobromide, - scopine 3, 3',4,4'-tetrafluorobenzilic acid ester methobromide, scopine 4,4'-diiluorobenzilic acid ester methobromide, tropenol 4,4Pdifluorobenzilic acid ester methobromide, scopine 3,3'-difluorobenzilic acid ester methobromide, and tropenol 3,3Pdifluorobenzilic acid ester methobromide.
• compositions according to the invention may contain the compounds of formula lb optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
• anticholinergic agents 1 are in a yet another preferred embodiment selected from the compounds of formula lc
• a and X ⁇ may have the meanings as mentioned hereinbefore, and wherein
• R 15 denotes hydrogen, hydroxy, methyl, ethyl, -CF3, CHF2 or fluorine;
• R r and R 2 which may be identical or different denote C ⁇ -C5-alkyl which may optionally be substituted by C3-Cg-cycloalkyl, hydroxy or halogen, or R 1 and R 2 together denote a -C3-C5-alkylene-bridge;
• R 13 , R 14 , R 13' and R 14' which may be identical or different denote hydrogen, -C ⁇ -C4-alkyl, -C ⁇ -C4-alkyloxy, hydroxy, -CF3, -CHF2, CN, NO2 or halogen.
• X denotes an anion selected from among chloride, bromide and methanesulphonate, preferably bromide;
• R 15 denotes hydroxy, methyl or fluorine, preferably methyl or hydroxy;
• R 1' andR which may be identical or different represent methyl or ethyl, preferably methyl;
• R 13 , R 14 , R 13 andR 14' which may be identical or different represent hydrogen, -CF3, -CFJF2 or fluorine, preferably hydrogen or fluorine.
• Particularly preferred within the combinations according to the invention are compounds of general formula lc, wherein
• A denotes a double-bonded group selected from among
• X denotes bromide
• R 15 denotes hydroxy or methyl, preferably methyl
• R 1 and R 2 which may be identical or different represent methyl or ethyl, preferably methyl; R 13 , R 14 , R 13' and R 14' which may be identical or different represent hydrogen or fluorine.
• compositions that contain the compound of formula 2 in combination with one of the following compounds lc: tropenol 9-hydroxy-fluorene-9-carboxylate methobromide ; tropenol 9-fluoro-fluorene-9-carboxylate methobromide ; - scopine 9-hydroxy-fluorene-9-carboxylate methobromide ; scopine 9-fluoro-fluorene-9-carboxylate methobromide ; tropenol 9-methyl-fluorene-9-carboxylate methobromide ; scopine 9-methyl-fluorene-9-carboxylate methobromide .
• compositions according to the invention may contain the compounds of formula lc optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
• anticholinergic agents 1 are in a yet another preferred embodiment selected from the compounds of formula Id
• R 16 denotes hydrogen, hydroxy, -C ⁇ -C4-alkyl, -C ⁇ C4-alkyloxy, -Cj-C4-alkylene-Halogen, -O-C ⁇ -C4-alkylene-halogen, -C ⁇ -C4-alkylene-OH, -CF 3 , CHF 2 , -C ⁇ -C4-alkylene-C 1 -C 4 -alkyloxy, -O- COC!-C4-alkyl, -O-COC ⁇ -C4-alkylene-halogen, -C] -C4-alkylene-C3-C r 5-cycloalkyl, -O-COCF3 or halogen; R 1 and R ⁇ which may be identical or different, denote -C ⁇ -C5-alkyl, which may optionally be substituted by -C3-C5-cycloalkyl, hydroxy or halogen, or R and R ,2" together de
• R x and R x ' which may be identical or different, denote hydrogen, C -C4-alkyl, C ⁇ -C4-alkyloxy, hydroxy, -CF3, -CHF2, CN, NO2 or halogen or R x and R x together denote a single bond or a bridging group selected from among the bridges -O, -S, -NH, -CH 2 , -CH2-CH2-, -N(C!-C4-alkyl), -CH(C 1 -C 4 -alkyl)- and -C(C 1 -C 4 -alkyl) .
• X denotes chloride, bromide, or methanesulphonate, preferably bromide
• R 16 denotes hydrogen, hydroxy, -C ⁇ C4-alkyl, -C ⁇ -C4-alk loxy, -CF3, -CHF2, fluorine, chlorine or bromine
• R 1 and R 2 which may be identical or different, denote C;[-C4-alkyl, which may optionally be substituted by hydroxy, fluorine, chlorine or bromine, or R 1 ' and R 2" together denote a -C3-C4-alkylene-bridge;
• R 17 , R 18 , R 17' and R 18 which may be identical or different, denote hydrogen, Cl-C4-alkyl, Cl-C4-alkyloxy, hydroxy, -CF3, -CHF2, CN, NO2, fluorine, chlorine or bromine;
• R x and R x ' which may be identical or different, denote hydrogen, C j -C4-alkyl, C ⁇ -C4-alkyloxy, hydroxy, -CF3, -CFJF2, CN, NO2, fluorine, chlorine or bromine or R x and R x together denote a single bond or a bridging group selected from among the bridges -O, -S, -NH- and -CH2- .
• X ⁇ denotes chloride, bromide, or methanesulphonate, preferably bromide
• R 16 denotes hydrogen, hydroxy or methyl;
• R 1 and R 2" which may be identical or different, denote methyl or ethyl;
• R 17 , R 18 , R 17' and R 18' which may be identical or different, denote hydrogen, -CF3 or fluorine, preferably hydrogen;
• R x and R x ' which may be identical or different, denote hydrogen, -CF3 or fluorine, preferably hydrogen or R x and R x together denote a single bond or the bridging group -O-.
• R 1" and R , 2" denote methyl
• R 17 , R 18 , R 17' and R 18' which may be identical or different, denote hydrogen or fluorine, preferably hydrogen;
• R x and R x ' which may be identical or different, denote hydrogen or fluorine, preferably hydrogen or R x and R x together denote a single bond or the bridging group -O-.
• compositions that contain the compound of formula 2 in combination with one of the following compounds Id: cyclopropyltropine benzilate methobromide; cyclopropyltropine 2,2-diphenylpropionate methobromide; cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide; cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide; - cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide; cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide ; cyclopropyltropine methyl 4,4'-difluorobenzilate methobromide.
• compositions according to the invention may contain the compounds of formula Id optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
• anticholinergic agents 1 are in a yet another preferred embodiment selected from the compounds of formula le
• R 19 denotes hydroxy, methyl, hydroxymethyl, ethyl, -CF3, CHF2 or fluorine;
• R 1 " and R 2 " which may be identical or different denote Cj-Cs-alkyl which may optionally be substituted by C3-Cg-cycloalkyl, hydroxy or halogen, or R 1'" and R 2 together denote a -C3-C5-alkylene-bridge;
• R 20 , R 21 , R 20' and R 21' which may be identical or different denote hydrogen, -C ⁇ -C4-alkyl, -C ⁇ -C4-alkyloxy, hydroxy, -CF3, -CHF2, CN, NO2 or halogen.
• X _ denotes chloride, bromide or methanesulphonate, preferably bromide
• R 19 denotes hydroxy or methyl
• R 1" and R 2 which may be identical or different represent methyl or ethyl, preferably methyl;
• R 20 , R 21 , R 20 and R 21' which may be identical or different represent hydrogen, -CF3, - CHF2 or fluorine, preferably hydrogen or fluorine.
• X ' denotes bromide
• R 19 denotes hydroxy or methyl , preferably methyl ;
• R 1 and R 2'" which may be identical or different represent methyl or ethyl, preferably methyl;
• R3' an d R4' n ich may be identical or different represent hydrogen or fluorine.
• compositions that contain the compound of formula 2 in combination with one of the following compounds le: tropenol 9-hydroxy-xanthene-9-carboxylate methobromide ; scopine 9-hydroxy-xanthene-9-carboxylate methobromide ; tropenol 9-methyl-xanthene-9-carboxylate methobromide ; - scopine 9-methyl-xanthene-9-carboxylate methobromide ; tropenol 9-ethyl-xanthene-9-carboxylate methobromide ; tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide ; scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide .
• compositions according to the invention may contain the compounds of formula le optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.
• alkyl groups used are branched and unbranched alkyl groups having 1 to 5 carbon atoms. Examples include: methyl, ethyl, propyl or butyl. The groups methyl, ethyl, propyl or butyl may optionally also be referred to by the abbreviations Me, Et, Prop or Bu. Unless otherwise stated, the definitions propyl and butyl also include all possible isomeric forms of the groups in question. Thus, for example, propyl includes n- propyl and iso-propyl, butyl includes iso-butyl, sec. butyl and tert. -butyl, etc.
• cycloalkyl groups used are alicyclic groups with 3 to 6 carbon atoms. These are the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups. According to the invention cyclopropyl is of particular importance within the scope of the present invention.
• alkylene groups used are branched and unbranched double- bonded alkyl bridges with 1 to 5 carbon atoms. Examples include: methylene, ethylene, propylene or butylene.
• the alkylene-halogen groups used, unless otherwise stated, are branched and unbranched double-bonded alkyl bridges with 1 to 4 carbon atoms which may be mono-, di- or trisubstituted, preferably disubstituted, by a halogen.
• alkylene-OH groups denotes branched and unbranched double-bonded alkyl bridges with 1 to 4 carbon atoms which may be mono-, di- or trisubstituted, preferably monosubstituted, by a hydroxy.
• alkyloxy groups used are branched and unbranched alkyl groups with 1 to 5 carbon atoms which are linked via an oxygen atom.
• the following may be mentioned, for example: methyloxy, ethyloxy, propyloxy or butyloxy.
• the groups methyloxy, ethyloxy, propyloxy or butyloxy may optionally also be referred to by the abbreviations MeO, EtO, PropO or BuO.
• the definitions propyloxy and butyloxy also include all possible isomeric forms of the groups in question.
• propyloxy includes n-propyloxy and iso-propyloxy
• butyloxy includes iso-butyloxy, sec.
• the word alkoxy may also possibly be used within the scope of the present invention instead of the word alkyloxy.
• the groups methyloxy, ethyloxy, propyloxy or butyloxy may optionally also be referred to as methoxy, ethoxy, propoxy or butoxy.
• alkylene-alkyloxy groups used are branched and unbranched double-bonded alkyl bridges with 1 to 5 carbon atoms which may be mono-, di- or trisubstituted, preferably monosubstituted, by an alkyloxy group.
• the -O-CO-alkyl groups used are branched and unbranched alkyl groups with 1 to 4 carbon atoms which are bonded via an ester group.
• the alkyl groups are bonded directly to the carbonylcarbon of the ester group.
• the term -O-CO-alkyl-halogen group should be understood analogously.
• the group -O-CO-CF3 denotes trifluoroacetate.
• halogen denotes fluorine, chlorine, bromine or iodine. Unless otherwise stated, fluorine and bromine are the preferred halogens.
• the group CO denotes a carbonyl group.
• any reference to the compounds V_ is to be regarded as a reference to the pharmacologically active cations contained in the salts 1. These are the cations of the following formulae
• anticholinergics 1 denotes the aforementioned salts optionally in form of their hydrates or solvates.
• pegsunercept is also expressed by the number 2.
• the pharmaceutical combinations of 1 and 2 according to the invention ' are preferably administered by inhalation. Suitable inhalable powders packed into suitable capsules (inhalettes) may be administered using suitable powder inhalers. The drug may also be inhaled using suitable solutions of the pharmaceutical combination consisting of 1 and 2.
• the invention relates to a pharmaceutical composition which contains a combination of 1 and 2.
• the present invention relates to a pharmaceutical composition which contains one or more salts 1 and one or more compounds 2, optionally in the form of their solvates or hydrates.
• the active substances may be combined in a single preparation or contained in two separate formulations.
• Pharmaceutical compositions which contain the active substances 1 and 2 in a single preparation are preferred according to the invention.
• the present invention relates to a pharmaceutical composition which contains, in addition to therapeutically effective quantities of 1 and 2, a pharmaceutically acceptable excipient.
• a pharmaceutical composition which does not contain any pharmaceutically acceptable excipient in addition to therapeutically effective quantities of 1 and 2.
• the present invention also relates to the use of 1 and 2 for preparing a pharmaceutical composition containing therapeutically effective quantities of 1 and 2 for treating inflammatory and/or obstructive diseases of the respiratory tract, particularly asthma or chronic obstructive pulmonary disease (COPD).
• inflammatory and/or obstructive diseases of the respiratory tract particularly asthma or chronic obstructive pulmonary disease (COPD).
• COPD chronic obstructive pulmonary disease
• Other diseases where the combination is useful are inflammatory diseases of the lung associated with fibrosis, such as cystic fibrosis and iodiopathic pulmonary fibrosis and inflammatory diseases of the upper airways such as rhinitis.
• the present invention also relates to the use of 1 for preparing a pharmaceutical composition for treating inflammatory and/or obstructive diseases of the respiratory tract, particularly asthma or chronic obstructive pulmonary disease (COPD), characterized in that a therapeutically effective quantity of 2 is used as well.
• inflammatory and/or obstructive diseases of the respiratory tract particularly asthma or chronic obstructive pulmonary disease (COPD)
• COPD chronic obstructive pulmonary disease
• the present invention also relates to the simultaneous or successive use of therapeutically effective doses of the combination of the above pharmaceutical compositions 1 and 2 for treating inflammatory and/or obstructive diseases of the respiratory tract, particularly asthma or chronic obstructive pulmonary disease (COPD) as well as allergic and non- allergic rhinitis, cystic fibrosis, and iodiopathic pulmonary fibrosis by simultaneous or successive administration.
• inflammatory and/or obstructive diseases of the respiratory tract particularly asthma or chronic obstructive pulmonary disease (COPD) as well as allergic and non- allergic rhinitis, cystic fibrosis, and iodiopathic pulmonary fibrosis by simultaneous or successive administration.
• COPD chronic obstructive pulmonary disease
• ingredient 1 may be present in the form of enantiomers, mixtures of enantiomers or in the form of racemates, whilst ingredient 2 may be present as a glycosylated protein whereby the degree and type of glycosylation may be varied.
• the proportions in which the two active substances 1 and 2 may be used in the active substance combinations according to the invention are variable. Active substances 1 and 2 may possibly be present in the form of their solvates or hydrates. Depending on the choice of the compounds 1 and 2, the weight ratios which may be used within the scope of the present invention vary on the basis of the different molecular weights of the various compounds and their different potencies.
• the pharmaceutical combinations according to the invention may contain compounds 1 and 2 in ratios by weight ranging from 1:2000 to 1:1, preferably from 1:1000 to 1:2.
• the weight ratios of 1 to 2 are most preferably in a range in which V_ and 2 are present in proportions of 1 :250 to 1 :3, more preferably from 1:100 to 1:5.
• preferred combinations of 1 and 2 according to the invention may contain and pegsunercept 2 in the following weight ratios: 1:200 1:100; 1:90; 1:85; 1:80; 1:75; 1:70; 1:65; 1:60; 1:55; 1:50; 1:49; 1:48; 1:47; 1:46; 1:45; 1:44; 1:43; 1:42; 1:41 1:40; 1:39; 1:38; 1:37; 1:36; 1:35; 1:34; 1:33; 1:32; 1:31; 1:30; 1:29; 1:28; 1:27; 1:26 1:25; 1:24; 1:23; 1:22; 1:21; 1:20; 1:19; 1:18; 1:17; 1:16; 1:15; 1:14; 1:13; 1:12; 1:11 1:10; 1:9; 1:8; 1:7; 1:6; 1:5.
• compositions according to the invention containing the combinations of 1 and 2 are normally administered so that 1 and 2 are present together in doses of 1 to lOOOO ⁇ g, preferably from 10 to 5000 ⁇ g, more preferably from 100 to 5000 ⁇ g, better still from 1000 to 2000 ⁇ g per single dose.
• combinations of 1 and 2 according to the invention contain a quantity of for instance la ⁇ and 2 such that the total dosage per single dose is about 2OO ⁇ g, 205 ⁇ g, 210 ⁇ g, 215 ⁇ g, 220 ⁇ g, 225 ⁇ g, 230 ⁇ g, 235 ⁇ g, 240 ⁇ g, 245 ⁇ g, 250 j Ug, 255 ⁇ g, 260 ⁇ g, 265 ⁇ g, 270 ⁇ g, 275 ⁇ g, 280 ⁇ g, 285/ g, 290 ⁇ g, 295/xg, 300 ⁇ g, 305 ⁇ g, 310 ⁇ g, 315 ⁇ g, 320 ⁇ g, 325 ⁇ g, 330 ⁇ g, 335 ⁇ g, 340 ⁇ g, 345 ⁇ g, 350 ⁇ g, 355 ⁇ g, 360 ⁇ g, 365 ⁇ g, 370 ⁇ g, 375 ⁇ g, 380 ⁇ g, 385 ⁇ g, 390 ⁇ g, 395 ⁇ g, 400 ⁇ g, 405 ⁇ g, 410 ⁇ g, 415 ⁇ g, 420
• the combinations of 1 and 2 according to the invention may contain a quantity of laL and pegsunercept 2 such that, for each single dose, 20 ⁇ g of la and 50 ⁇ g of 2, 20 ⁇ g of la ⁇ and 50 ⁇ g of 2, 20 ⁇ g of 1 and lOO ⁇ g of 2, 20 ⁇ g of la ⁇ and 200 ⁇ g of 2, 20 ⁇ g of 1 and 300 ⁇ g of 2, 20 ⁇ g of la ⁇ and 400 ⁇ g of 2, 20 ⁇ g of ! and 500 tg of 2, 20 ⁇ g of ! and 600 ⁇ g of 2, 20 ⁇ g of !
• the total amount of salt la is readily calculable for the person of ordinary skill in the art, taking into account the mass of the anion of choice (e.g. bromide).0
• the aforementioned examples of possible doses applicable for the combinations according to the invention are to be understood as referring to doses per single application. However, these examples are not be understood as excluding the possibility of administering the combinations according to the invention multiple times.
• patients may receive also multiple inhalative applications. As an example patients may receive the combinations according to the invention for instance two or three times (e.g. two or three puffs with a powder inhaler, an MDI etc) in the morning of each treatment day.
• the aforementioned dose examples are only to be understood as dose examples per single application (i.e. per puff) multiple application of the combinations according to the invention leads to multiple doses of the aforementioned examples.
• the application of the combositions according to the invention can be for instance once a day, or depending on the duration of action of the anticholinergic agent twice a day, or once every 2 or 3 days.
• the aforementioned dose examples are to be understood as examples of metered doses only. In other terms, the aforementioned dose examples are not to be understood as the effective doses of the combinations according to the invention that do in fact reach the lung. It is clear for the person of ordinary skill in the art that the delivered dose to the lung is generally lower than the metered dose of the administered active ingredients.
• the active substance combinations of 1 and 2 according to the invention are preferably administered by inhalation.
• ingredients 1 and 2 have to be made available in forms suitable for inhalation.
• Inhalable preparations include inhalable powders and inhalable solutions.
• Inhalable powders according to the invention containing the combination of active substances 1 and 2 may consist of the active substances on their own or of a mixture of the active substances with physiologically acceptable excipients.
• inhalable solutions also includes concentrates or sterile inhalable solutions ready for use in a nebuliser.
• the preparations according to the invention may contain the combination of active substances 1 and 2 either together in one formulation or in two separate formulations. These formulations which may be used within the scope of the present invention are described in more detail in the next part of the specification. ) Inhalable powder containing the combinations of active substances 1 and 2 according to the invention:
• the inhalable powders according to the invention may contain 1 and 2 either on their own or in admixture with suitable physiologically acceptable excipients.
• physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose, trehalose), oligo- and polysaccharides (e.g. dextran), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients with one another.
• monosaccharides e.g. glucose or arabinose
• disaccharides e.g. lactose, saccharose, maltose, trehalose
• oligo- and polysaccharides e.g. dextran
• polyalcohols e.g. sorbitol, mannitol, xylitol
• salts e.g. sodium chloride, calcium carbon
• lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
• the excipients have a maximum mass mean aerodynamic diameter of up to 250 ⁇ m, preferably between 10 and 150 ⁇ m, most preferably between 15 and 80 ⁇ m. It may sometimes seem appropriate to add finer excipient fractions with an mass mean aerodynamic diameter of 1 to 9 ⁇ m to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore.
• active substance 1 and 2 preferably with an mass mean aerodynamic diameter of 0.5 to lO ⁇ m, more preferably from 1 to 5 ⁇ m, is added to the excipient mixture.
• Processes for producing the inhalable powders according to the invention and finally mixing the ingredients together are known from the prior art. These processes may include, but are not limited to, spray drying or grinding and micronising. Particularly favoured are processes which protect the protein component from denaturation during the production of particles of the right size range to be suitable for inhalation.
• the inhalable powders according to the invention may be prepared and administered either in the form of a single powder mixture which contains both 1 and 2 or in the form of separate inhalable powders which contain only 1 or 2.
• the inhalable powders according to the invention may be administered using inhalers known from the prior art.
• Inhalable powders according to the invention which contain a physiologically acceptable excipient in addition to 1 and 2 may be administered, for example, by means of inhalers which deliver a single dose from a supply using a measuring chamber as described in US 4570630A, or by other means as described in DE 36 25 685 A.
• the inhalable powders according to the invention which contain physiologically acceptable excipient in addition to 1 and 2 are packed into capsules (to produce so-called inhalettes) which are used in inhalers as described, for example, in WO 94/28958.
• FIG. 1 A particularly preferred inhaler for using the pharmaceutical combination according to the invention in inhalettes is shown in Figure 1.
• This inhaler for inhaling powdered pharmaceutical compositions from capsules is characterised by a housing 1 containing two windows 2, a deck 3 in which there are air inlet ports and which is provided with a screen 5 secured via a screen housing 4, an inhalation chamber 6 connected to the deck 3 on which there is a push button 9 provided with two sharpened pins 7 and movable counter to a spring 8, a mouthpiece 12 which is connected to the housing 1, the deck 3 and a cover 11 via a spindle 10 to enable it to be flipped open or shut and three holes 13 with diameters below 1 mm in the central region around the capsule chamber 6 and underneath the screen housing 4 and screen 5.
• the main air flow enters the inhaler between deck 3 and base 1 near to the hinge.
• the deck has in this range a reduced width, which forms the entrance slit for the air. Then the flow reverses and enters the capsule chamber 6 through the inlet tube. The flow is then further conducted through the filter and filter holder to the mouthpiece. A small portion of the flow enters the device between mouthpiece and deck and flows then between filterholder and deck into the main stream. Due to production tolerances there is some uncertainty in this flow because of the actual width of the slit between filterholder and deck. In case of new or reworked tools the flow resistance of the inhaler may therefore be a little off the target value. To correct this deviation the deck has in the central region around the capsule chamber 6 and underneath the screen housing 4 and screen 5 three holes 13 with diameters below 1 mm. Through these holes 13 flows air from the base into the main air stream and reduces such slightly the flow resistance of the inhaler. The actual diameter of these holes 13 can be chosen by proper inserts in the tools so that the mean flow resistance can be made equal to the target value.
• the quantities packed into each capsule should be 1 to 30mg, preferably 3 to 20mg, more particularly 5 to lOmg of inhalable powder per capsule.
• These capsules contain, according to the invention, either together or separately, the doses of and 2 mentioned hereinbefore for each single dose.
• the active substance combination according to the invention is used in the form of inhalable solutions and suspensions.
• the solvent / suspending agent used may be aqueous or alcoholic, preferably ethanolic.
• the solvent / suspending agent may be water on its own or a mixture of water and ethanol.
• the relative proportion of ethanol compared with water is not limited (other than by the requirement that it not precipitate or cause irreversible denaturation of the protein component of the mixture), but the maximum is up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume.
• the remainder of the volume is made up of water.
• the solutions or suspensions containing 1 and 2, separately or together, are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids.
• the pH may be adjusted using acids selected from inorganic or organic acids.
• suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid.
• particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc.
• Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances.
• ascorbic acid, fumaric acid and citric acid are preferred.
• mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example.
• hydrochloric acid it is particularly preferred to use hydrochloric acid to adjust the pH.
• the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent is unnecessary in the present formulation.
• Other embodiments may contain this compound or these compounds.
• the content based on sodium edetate is less than lOOmg/lOOml, preferably less than 50mg 100 ml, more preferably less than 20mg/100 ml.
• inhalable solutions in which the content of sodium edetate is from 0 to 10mg/ 100ml are preferred.
• Co-solvents and/or other excipients may be added to the inhalable solutions according to the invention.
• Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
• excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the pharmacologically suitable solvent in order to improve the qualitative properties of the active substance formulation.
• these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect.
• the excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art.
• the additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
• the preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
• Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art.
• the preservatives mentioned above are preferably present in concentrations of up to 50mg/100ml, more preferably between 5 and
• Preferred formulations contain, in addition to the solvent water and the combination of active substances 1 and 2, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no sodium edetate is present.
• inhalable solutions according to the invention are administered in particular using inhalers of the kind which are capable of nebulising a small amount of a liquid formulation in the therapeutic dose within a few seconds to produce an aerosol suitable for therapeutic inhalation.
• preferred inhalers are those in which a quantity of less than lOO ⁇ L, preferably less than 50 ⁇ L, more preferably between 10 and 30 ⁇ L of active substance solution can be nebulised in preferably one spray action to form an aerosol with an mass mean aerodynamic diameter of less than 20 ⁇ m, preferably less than lO ⁇ m, in such a way that the inhalable part of the aerosol corresponds to the therapeutically effective quantity.
• nebulisers devices described therein are known by the name Respimat®.
• This nebuliser can advantageously be used to produce the inhalable aerosols according to the invention containing the combination of active substances 1 and 2. Because of its cylindrical shape and handy size of less than 9 to 15 cm long and 2 to 4 cm wide, this device can be carried at all times by the patient.
• the nebuliser sprays a defined volume of pharmaceutical formulation using high pressures through small nozzles so as to produce inhalable aerosols.
• the preferred atomiser essentially consists of an upper housing part, a pump housing, a nozzle, a locking mechanism, a spring housing, a spring and a storage container, characterised by - a pump housing which is secured in the upper housing part and which comprises at one end a nozzle body with the nozzle or nozzle arrangement, - a hollow plunger with valve body, - a power takeoff flange in which the hollow plunger is secured and which is located in the upper housing part, a locking mechanism situated in the upper housing part, - a spring housing with the spring contained therein, which is rotatably mounted on the upper housing part by means of a rotary bearing, - a lower housing part which is fitted onto the spring housing in the axial direction.
• the hollow plunger with valve body corresponds to a device disclosed in WO 97/12687. It projects partially into the cylinder of the pump housing and is axially movable within the cylinder. Reference is made in particular to Figures 1 to 4, especially Figure 3, and the relevant parts of the description.
• the hollow plunger with valve body exerts a pressure of 5 to 60 Mpa (about 50 to 600 bar), preferably 10 to 60 Mpa (about 100 to 600 bar) on the fluid, the measured amount of active substance solution, at its high pressure end at the moment when the spring is actuated. Volumes of 10 to 50 microlitres are preferred, while volumes of 10 to 20 microlitres are particularly preferred and a volume of 15 microlitres per spray is most particularly preferred.
• the valve body is preferably mounted at the end of the hollow plunger facing the valve body.
• the nozzle in the nozzle body is preferably microstructured, i.e. produced by microtechnology.
• Microstructured nozzle bodies are disclosed for example in WO-94/07607; reference is hereby made to the contents of this specification, particularly Figure 1 therein and the associated description.
• the nozzle body consists for example of two sheets of glass and/or silicon firmly joined together, at least one of which has one or more microstructured channels which connect the nozzle inlet end to the nozzle outlet end.
• At the nozzle outlet end there is at least one round or non -round opening 2 to 10 microns deep and 5 to 15 microns wide, the depth preferably being 4.5 to 6.5 microns while the length is preferably 7 to 9 microns.
• the directions of spraying of the nozzles in the nozzle body may extend parallel to one another or may be inclined relative to one another in the direction of the nozzle opening.
• the directions of spraying may be at an angle of 20 to 160° to one another, preferably 60 to 150°, most preferably 80 to 100°.
• the nozzle openings are preferably arranged at a spacing of 10 to 200 microns, more preferably at a spacing of 10 to 100 microns, most preferably 30 to 70 microns. Spacings of 50 microns are most preferred.
• the directions of spraying will therefore meet in the vicinity of the nozzle openings.
• the liquid pharmaceutical preparation strikes the nozzle body with an entry pressure of up to 600 bar, preferably 200 to 300 bar, and is atomised into an inhalable aerosol through the nozzle openings.
• the preferred particle or droplet sizes of the aerosol are up to 20 microns, preferably 3 to 10 microns.
• the locking mechanism contains a spring, preferably a cylindrical helical compression spring, as a store for the mechanical energy.
• the spring acts on the power takeoff flange as an actuating member the movement of which is determined by the position of a locking member.
• the travel of the power takeoff flange is precisely limited by an upper and lower stop.
• the spring is preferably biased, via a power step-up gear, e.g. a helical thrust gear, by an external torque which is produced when the upper housing part is rotated counter to the spring housing in the lower housing part.
• the upper housing part and the power takeoff flange have a single or multiple V-shaped gear.
• the locking member with engaging locking surfaces is arranged in a ring around the power takeoff flange. It consists, for example, of a ring of plastic or metal which is inherently radially elastically deformable.
• the ring is arranged in a plane at right angles to the atomiser axis. After the biasing of the spring, the locking surfaces of the locking member move into the path of the power takeoff flange and prevent the spring from relaxing.
• the locking member is actuated by means of a button.
• the actuating button is connected or coupled to the locking member. In order to actuate the locking mechanism, the actuating button is moved parallel to the annular plane, preferably into the atomiser; this causes the deformable ring to deform in the annual plane. Details of the construction of the locking mechanism are given in WO 97/20590.
• the lower housing part is pushed axially over the spring housing and covers the mounting, the drive of the spindle and the storage container for the fluid.
• the upper housing part When the atomiser is actuated the upper housing part is rotated relative to the lower housing part, the lower housing part taking the spring housing with it.
• the spring is thereby compressed and biased by means of the helical thrust gear and the locking mechanism engages automatically.
• the angle of rotation is preferably a whole-number fraction of 360 degrees, e.g. 180 degrees.
• the power takeoff part in the upper housing part is moved along by a given distance, the hollow plunger is withdrawn inside the cylinder in the pump housing, as a result of which some of the fluid is sucked out of the storage container and into the high pressure chamber in front of the nozzle.
• a number of exchangeable storage containers which contain the fluid to be atomised may be pushed into the atomiser one after another and used in succession.
• the storage container contains the aqueous aerosol preparation according to the invention.
• the atomising process is initiated by pressing gently on the actuating button.
• the locking mechanism opens up the path for the power takeoff member.
• the biased spring pushes the plunger into the cylinder of the pump housing.
• the fluid leaves the nozzle of the atomiser in atomised form.
• the components of the atomiser are made of a material which is suitable for its purpose.
• the housing of the atomiser and, if its operation permits, other parts as well are preferably made of plastics, e.g. by injection moulding.
• physiologically safe materials are used for medicinal purposes.
• Figures 6a b of WO 97/12687 show the nebuliser (Respimat®) which can advantageously be used for inhaling the aqueous aerosol preparations according to the invention.
• Figure 6a of WO 97/12687 shows a longitudinal section through the atomiser with the spring biased while Figure 6b shows a longitudinal section through the atomiser with the spring relaxed.
• the upper housing part (51) contains the pump housing (52) on the end of which is mounted the holder (53) for the atomiser nozzle.
• the nozzle body (54) In the holder is the nozzle body (54) and a filter (55).
• the hollow plunger (57) fixed in the power takeoff flange (56) of the locking mechanism projects partially into the cylinder of the pump housing.
• the hollow plunger carries the valve body (58).
• the hollow plunger is sealed off by means of the seal (59).
• Inside the upper housing part is the stop (60) on which the power takeoff flange abuts when the spring is relaxed.
• the stop (61) On the power takeoff flange is the stop (61) on which the power takeoff flange abuts when the spring is biased.
• the locking member (62) moves between the stop (61) and a support (63) in the upper housing part.
• the actuating button (64) is connected to the locking member.
• the upper housing part ends in the mouthpiece (65) and is sealed off by means of the protective cover (66) which can be placed thereon.
• the spring housing (67) with compression spring (68) is rotatably mounted on the upper housing part by means of the snap-in lugs (69) and rotary bearing.
• the lower housing part (70) is pushed over the spring housing.
• the exchangeable storage container (71) for the fluid (72) which is to be atomised.
• the storage container is sealed off by the stopper (73) through which the hollow plunger projects into the storage container and is immersed at its end in the fluid (supply of active substance solution).
• the spindle (74) for the mechanical counter is mounted in the covering of the spring housing. At the end of the spindle facing the upper housing part is the drive pinion (75). The slider (76) sits on the spindle.
• the nebuliser described above is suitable for nebulising the aerosol preparations according to the invention to produce an aerosol suitable for inhalation.
• the quantity delivered should correspond to a defined quantity with a tolerance of not more than 25%, preferably 20% of this amount in at least 97%, preferably at least 98% of all operations of the inhaler (spray actuations).
• a tolerance of not more than 25% preferably 20% of this amount in at least 97%, preferably at least 98% of all operations of the inhaler (spray actuations).
• spray actuations Preferably, between 5 and 30 mg of formulation, most preferably between 5 and 20 mg of formulation are delivered as a defined mass on each actuation.
• formulation according to the invention may also be nebulised by means of inhalers other than those described above, e.g. jet stream inhalers.
• the invention relates to pharmaceutical formulations in the form of inhalable solutions or suspensions as described above combined with a device suitable for administering these formulations, preferably in conjunction with the Respimat®.
• the invention relates to inhalable solutions or suspensions characterised by the combination of active substances 1 and 2 according to the invention in conjunction with the device known by the name Respimat®.
• the present invention relates to the above-mentioned devices for inhalation, preferably the Respimat®, characterised in that they contain the inhalable solutions or suspensions according to the invention as described hereinbefore.
• the inhalable solutions or suspensions according to the invention may take the form of concentrates or sterile inhalable solutions or suspensions ready for use, as well as the above-mentioned solutions and suspensions designed for use in a Respimat®.
• Formulations ready for use may be produced from the concentrates, for example, by the addition of isotonic saline solutions.
• Sterile formulations ready for use may be administered using energy-operated fixed or portable nebulisers which produce inhalable aerosols by means of ultrasound or compressed air by the Nenturi principle or other principles.
• the present invention relates to pharmaceutical compositions in the form of inhalable solutions or suspensions as described hereinbefore which take the form of concentrates or sterile formulations ready for use, combined with a device suitable for administering these solutions, characterised in that the device is an energy-operated free-standing or portable nebuliser which produces inhalable aerosols by means of ultrasound or compressed air by the Nenturi principle or other methods.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pulmonology (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Otolaryngology (AREA)
• Immunology (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Emergency Medicine (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=34878167

Family Applications (1)

Country Status (4)

Families Citing this family (1)

Family Cites Families (6)

• 2005
  • 2005-02-18 EP EP05707495A patent/EP1718301A1/de not_active Withdrawn
  • 2005-02-18 JP JP2006553541A patent/JP2007523116A/ja active Pending
  • 2005-02-18 WO PCT/EP2005/001677 patent/WO2005079794A1/en not_active Application Discontinuation
  • 2005-02-18 CA CA002552903A patent/CA2552903A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events